Jefferies Financial Group Inc. Acquires New Holdings in Xeris Biopharma Holdings, Inc. $XERS

Jefferies Financial Group Inc. acquired a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 87,800 shares of the company’s stock, valued at approximately $689,000.

Several other institutional investors also recently bought and sold shares of the business. Legato Capital Management LLC increased its holdings in Xeris Biopharma by 9.5% during the fourth quarter. Legato Capital Management LLC now owns 237,431 shares of the company’s stock valued at $1,864,000 after buying an additional 20,626 shares during the period. ProShare Advisors LLC increased its holdings in Xeris Biopharma by 10.6% during the fourth quarter. ProShare Advisors LLC now owns 35,390 shares of the company’s stock valued at $278,000 after buying an additional 3,383 shares during the period. Western Wealth Management LLC purchased a new position in Xeris Biopharma during the fourth quarter valued at approximately $594,000. Bailard Inc. purchased a new position in Xeris Biopharma during the fourth quarter valued at approximately $120,000. Finally, Swiss Life Asset Management Ltd purchased a new position in Xeris Biopharma during the fourth quarter valued at approximately $205,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on XERS shares. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xeris Biopharma has an average rating of “Hold” and an average price target of $10.80.

Xeris Biopharma Stock Down 2.5%

XERS opened at $6.16 on Friday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $10.08. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The company has a fifty day moving average of $6.04 and a two-hundred day moving average of $6.64. The stock has a market capitalization of $1.06 billion, a price-to-earnings ratio of 102.67 and a beta of 0.85.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.01 earnings per share for the quarter. The company had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Insider Transactions at Xeris Biopharma

In other news, Director James Aloysius Brady sold 10,834 shares of the business’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $5.54, for a total transaction of $60,020.36. Following the completion of the sale, the director owned 89,166 shares of the company’s stock, valued at $493,979.64. The trade was a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $6.23, for a total transaction of $103,835.41. Following the sale, the insider directly owned 1,193,173 shares of the company’s stock, valued at $7,433,467.79. This represents a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 60,835 shares of company stock valued at $367,860 in the last three months. Corporate insiders own 6.47% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.